‘Persistent delays’ in cancer drug approvals making Ireland among slowest in Europe for treatment

Cancer patients in Ireland are among the last in Europe to have access to certain drugs due to “persistent delays” approving medicines.

That is according to the representative body for the international research-based pharmaceutical industry the Irish Pharmaceutical Healthcare Association, the representative body for the international research-based pharmaceutical industry.